The historical rank and industry rank for Cansortium's EV-to-EBIT or its related term are showing as below:
XCNQ:TIUM.U'
s EV-to-EBIT Range Over the Past 10 Years
Min: -150.83 Med: -9.46 Max: 104.39
Current: 15.48
During the past 6 years, the highest EV-to-EBIT of Cansortium was 104.39. The lowest was -150.83. And the median was -9.46.
XCNQ:TIUM.U's EV-to-EBIT is ranked better than 55.54% of 668
companies
in the Drug Manufacturers industry
Industry Median: 17.155
vs XCNQ:TIUM.U: 15.48
The historical data trend for Cansortium's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cansortium's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cansortium's EV-to-EBIT Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cansortium's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cansortium's EV-to-EBIT falls into.
Cansortium EV-to-EBIT Calculation
Cansortium's EV-to-EBIT for today is calculated as:
Cansortium's current Enterprise Value is $136.57 Mil.
Cansortium's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cansortium (XCNQ:TIUM.U) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cansortium's Enterprise Value for the quarter that ended in Dec. 2023 was $115.85 Mil.
Cansortium's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cansortium EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Cansortium's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Cansortium Inc is licensed to produce and sell medical cannabis in Florida and Texas and is licensed to sell medical cannabis in Pennsylvania. Its medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flowers, pre-rolls, cartridges, and edibles. All of the company's products are marketed under the Fluent brand name. In Pennsylvania, the company's product portfolio is comprised of a variety of third-party branded medical cannabis products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XCNQ:TIUM.U has been successfully added to your 